Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.78 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.55 |
| ▸ | BRD2 | P25440 | 1/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.52 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.52 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.52 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6969297 | 0.91 | MAPK14 (0.75) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL29841930 | 0.90 | MAPK14 (0.67) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL28601290 | 0.90 | MAPK14 (0.67) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL27441160 | 0.88 | MAPK14 (1.00) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL6962054 | 0.87 | MAPK14 (0.71) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL6962734 | 0.86 | MAPK14 (0.75) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL4585618 | 0.85 | MAPK14 (1.00) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL4915665 | 0.85 | MAPK14 (0.80) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL28607656 | 0.84 | MAPK14 (0.70) | MAPK14BRD4BRDTBRD2BRD3 | |
| SCHEMBL28608792 | 0.84 | MAPK14 (0.70) | MAPK14BRD4BRDTBRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | SCIOS INC. | 2006-01-26 | — | — | US | disclosed |
| US-20050129729-A1 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. | 2005-06-16 | — | — | US | disclosed |
| EP-1539121-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1314728-A1 | Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6387898-B1 | USING IMIDAZOLE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-6218537-B1 | Process for making pyridyl and pyrimidine substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-1021173-A1 | USE OF CSAID?TM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018942-A1 | USE OF CSAIDTM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 1999-04-22 | — | — | WO | disclosed |
| US-5869660-A | Process of preparing imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| US-5739143-A | Imidazole compounds and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | MAPKAPK5, MAPK1, MAPKAPK2 | MAPK14 36/4885BRD4 1349/4885BRDT 3829/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MAPK14 23/4885BRD4 1516/4885BRDT 2959/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885BRD4 3147/4885BRDT 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.